Pfizer Inc SEC filings PFE
Pfizer Inc has 1,000 filings in SEC EDGAR's recent list, going back to Feb 26, 2021. Its latest annual report, Form ARS, was filed on Mar 12, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 27, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Mar 12, 2026 | — |
| DEF 14A | Proxy statement | Mar 12, 2026 | Apr 23, 2026 |
| DEFA14A | Additional proxy material | Apr 11, 2025 | — |
| DEFA14A | Additional proxy material | Apr 10, 2025 | — |
| DEFA14A | Additional proxy material | Apr 10, 2025 | — |
| DEFA14A | Additional proxy material | Apr 10, 2025 | — |
| DEFA14A | Additional proxy material | Apr 7, 2025 | — |
| DEFA14A | Additional proxy material | Mar 13, 2025 | — |
| DEF 14A | Proxy statement | Mar 13, 2025 | Apr 24, 2025 |
| DEFA14A | Additional proxy material | Apr 11, 2024 | — |
| DEFA14A | Additional proxy material | Apr 11, 2024 | — |
| DEFA14A | Additional proxy material | Apr 11, 2024 | — |
| DEFA14A | Additional proxy material | Apr 9, 2024 | — |
| DEFA14A | Additional proxy material | Mar 28, 2024 | — |
| DEFA14A | Additional proxy material | Mar 28, 2024 | — |
| DEFA14A | Additional proxy material | Mar 14, 2024 | — |
| DEF 14A | Proxy statement | Mar 14, 2024 | Apr 25, 2024 |
| DEFA14A | Additional proxy material | Apr 10, 2023 | — |
| DEFA14A | Additional proxy material | Apr 10, 2023 | — |
| DEFA14A | Additional proxy material | Mar 30, 2023 | — |
| DEFA14A | Additional proxy material | Mar 16, 2023 | — |
| DEF 14A | Proxy statement | Mar 16, 2023 | — |
| DEFA14A | Additional proxy material | Apr 22, 2022 | — |
| DEFA14A | Additional proxy material | Apr 11, 2022 | — |
| DEFA14A | Additional proxy material | Apr 6, 2022 | — |
| DEFA14A | Additional proxy material | Mar 30, 2022 | — |
| DEFA14A | Additional proxy material | Mar 17, 2022 | — |
| DEF 14A | Proxy statement | Mar 17, 2022 | Apr 28, 2022 |
| DEFA14A | Additional proxy material | Apr 15, 2021 | — |
| DEFA14A | Additional proxy material | Mar 29, 2021 | — |
| DEFA14A | Additional proxy material | Mar 12, 2021 | — |
| DEF 14A | Proxy statement | Mar 12, 2021 | Apr 22, 2021 |
Showing 32 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PFE (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 78003
- Former names
- PFIZER INC (until Nov 3, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.